Elon knows the truth, which is why they want him silenced

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.

Watch this new documentary and you’ll discover what Elon knows,

Dashyant Dhanak Biography and Net Worth

EVP of Incyte

Dash Dhanak joined Incyte in December of 2018 as Executive Vice President and Chief Scientific Officer. With 30 years of broad pharmaceutical and drug discovery experience, Dr. Dhanak joined Incyte from Janssen Research & Development, where, since 2013, he served as Vice President and Head of Discovery Sciences, leading the organization responsible for supporting and enabling the discovery and preclinical development of novel small molecule therapeutics. Prior to his tenure at Janssen, Dr. Dhanak spent 25 years at GlaxoSmithKline in positions of increased responsibility across multiple disease areas, including his last position as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit.

Dr. Dhanak received a Bachelor of Science in Chemistry from the University of Manchester Institute of Science and Technology and his PhD from the University of London, both in the United Kingdom. He completed his postdoctoral research in natural product synthesis at Northwestern University in Chicago, Illinois.

What is Dashyant Dhanak's net worth?: The estimated net worth of Dashyant Dhanak is at least $2.18 million as of September 8th, 2020. Dr. Dhanak owns 28,971 shares of Incyte stock worth more than $2,181,516 as of November 18th. This net worth estimate does not reflect any other investments that Dr. Dhanak may own. Learn More about Dashyant Dhanak's net worth.
How do I contact Dashyant Dhanak?: The corporate mailing address for Dr. Dhanak and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Dashyant Dhanak's contact information.
Has Dashyant Dhanak been buying or selling shares of Incyte?: Dashyant Dhanak has not been actively trading shares of Incyte over the course of the past ninety days. Most recently, Dashyant Dhanak sold 389 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $68.67, for a transaction totalling $26,712.63. Learn More on Dashyant Dhanak's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 58,851 shares worth more than $3,787,827.45. The most recent insider tranaction occured on November, 6th when EVP Barry P Flannelly sold 3,680 shares worth more than $293,222.40. Insiders at Incyte own 17.6% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 11/6/2024.

Dashyant Dhanak Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2021	Sell	389	$68.67	$26,712.63
9/1/2021	Sell	388	$76.71	$29,763.48
4/1/2021	Sell	396	$81.57	$32,301.72
9/8/2020	Sell	961	$88.94	$85,471.34	28,971
5/6/2020	Sell	961	$96.84	$93,063.24	20,948

Dashyant Dhanak Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $75.30

$75.30

50 Day Range

MA: $68.99

$62.26

$83.38

2 Week Range

Now: $75.30

$50.35

$83.95

Volume

5,969 shs

Average Volume

2,331,534 shs

Market Capitalization

$14.51 billion

P/E Ratio

537.90

Dividend Yield

N/A

Beta

0.71